Emerging therapies for Parkinson's disease.
Identifieur interne : 000372 ( Ncbi/Merge ); précédent : 000371; suivant : 000373Emerging therapies for Parkinson's disease.
Auteurs : Werner Poewe [Autriche] ; Philipp Mahlknecht ; Joseph Jankovic [États-Unis]Source :
- Current opinion in neurology ; 2012.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- chemical , classification : Antiparkinson Agents.
- therapy : Parkinson Disease.
- Clinical Trials as Topic, Drug Administration Routes, Drug Delivery Systems, Humans.
Abstract
The experimental therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.
DOI: 10.1097/WCO.0b013e3283542fde
PubMed: 22772874
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000053
- to stream PubMed, to step Curation: 000053
- to stream PubMed, to step Checkpoint: 000061
Links to Exploration step
pubmed:22772874Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging therapies for Parkinson's disease.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>University-Klinik für Neurologie, University of Innsbruck, Innsbruck, Austria. werner.poewe@i-med.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>University-Klinik für Neurologie, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="doi">10.1097/WCO.0b013e3283542fde</idno><idno type="RBID">pubmed:22772874</idno><idno type="pmid">22772874</idno><idno type="wicri:Area/PubMed/Corpus">000053</idno><idno type="wicri:Area/PubMed/Curation">000053</idno><idno type="wicri:Area/PubMed/Checkpoint">000061</idno><idno type="wicri:Area/Ncbi/Merge">000372</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging therapies for Parkinson's disease.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>University-Klinik für Neurologie, University of Innsbruck, Innsbruck, Austria. werner.poewe@i-med.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>University-Klinik für Neurologie, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j">Current opinion in neurology</title><idno type="e-ISSN">1473-6551</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (classification)</term><term>Clinical Trials as Topic</term><term>Drug Administration Routes</term><term>Drug Delivery Systems</term><term>Humans</term><term>Parkinson Disease (therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Drug Administration Routes</term><term>Drug Delivery Systems</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The experimental therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22772874</PMID><DateCreated><Year>2012</Year><Month>07</Month><Day>09</Day></DateCreated><DateCompleted><Year>2012</Year><Month>11</Month><Day>26</Day></DateCompleted><DateRevised><Year>2013</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6551</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current opinion in neurology</Title><ISOAbbreviation>Curr. Opin. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Emerging therapies for Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>448-59</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WCO.0b013e3283542fde</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The experimental therapeutics of Parkinson's disease are reviewed, highlighting the current pipeline of emerging therapeutic approaches.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">This review includes novel approaches to dopaminergic drug delivery such as intraintestinal infusions or new extended-release formulations of levodopa and also intrapulmonary delivery of apomorphine as well as novel dopaminergic agents like the monoamine oxidase-B inhibitor safinamide or novel catechol-O-methyl transferase inhibitors. An even greater number of ongoing clinical trials assess the efficacy and safety of nondopaminergic approaches to enhance motor control or reduce motor complications like fluctuations and dyskinesias. These include adenosine A2A antagonists, α-adrenergic and serotonergic agonists as well as drugs acting on the glutamatergic system. Gene-based or cell-based intrastriatal delivery of therapeutic principles that enhance striatal dopaminergic transmission directly or via the stimulation of trophic activity has also reached phase II clinical development with encouraging results in some studies. Finally, a wide spectrum of agents with a potential for slowing disease progression is currently tested.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">A variety of medical and nonmedical interventions in different phases of clinical development provide an interesting and promising portfolio of emerging therapies for Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>University-Klinik für Neurologie, University of Innsbruck, Innsbruck, Austria. werner.poewe@i-med.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahlknecht</LastName><ForeName>Philipp</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurol</MedlineTA><NlmUniqueID>9319162</NlmUniqueID><ISSNLinking>1350-7540</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004333">Drug Administration Routes</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D016503">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283542fde</ArticleId><ArticleId IdType="pii">00019052-201208000-00011</ArticleId><ArticleId IdType="pubmed">22772874</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><noCountry><name sortKey="Mahlknecht, Philipp" sort="Mahlknecht, Philipp" uniqKey="Mahlknecht P" first="Philipp" last="Mahlknecht">Philipp Mahlknecht</name></noCountry><country name="Autriche"><noRegion><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></noRegion></country><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000372 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000372 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22772874
|texte= Emerging therapies for Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22772874" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |